Dorsey Wright & Associates Buys New Stake in Genmab A/S Sponsored ADR $GMAB

Dorsey Wright & Associates bought a new stake in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 44,837 shares of the company’s stock, valued at approximately $1,381,000.

A number of other institutional investors also recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC increased its holdings in shares of Genmab A/S by 124.9% during the second quarter. EverSource Wealth Advisors LLC now owns 2,114 shares of the company’s stock valued at $44,000 after purchasing an additional 1,174 shares during the period. Sei Investments Co. lifted its holdings in Genmab A/S by 4.2% in the second quarter. Sei Investments Co. now owns 62,111 shares of the company’s stock worth $1,283,000 after purchasing an additional 2,496 shares during the period. Squarepoint Ops LLC lifted its holdings in Genmab A/S by 636.3% in the second quarter. Squarepoint Ops LLC now owns 94,233 shares of the company’s stock worth $1,947,000 after purchasing an additional 81,434 shares during the period. Quantinno Capital Management LP grew its position in Genmab A/S by 64.9% in the 2nd quarter. Quantinno Capital Management LP now owns 158,132 shares of the company’s stock valued at $3,267,000 after buying an additional 62,226 shares in the last quarter. Finally, Raymond James Financial Inc. grew its position in Genmab A/S by 48.1% in the 2nd quarter. Raymond James Financial Inc. now owns 31,146 shares of the company’s stock valued at $643,000 after buying an additional 10,113 shares in the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

Analyst Ratings Changes

GMAB has been the topic of a number of recent analyst reports. Truist Financial began coverage on shares of Genmab A/S in a research report on Wednesday, May 27th. They set a “buy” rating and a $40.00 price target on the stock. Wolfe Research began coverage on shares of Genmab A/S in a report on Friday, March 27th. They issued an “outperform” rating and a $32.00 price objective for the company. Weiss Ratings lowered shares of Genmab A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, May 8th. BNP Paribas Exane raised Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday, April 22nd. Finally, The Goldman Sachs Group raised Genmab A/S from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 22nd. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $37.93.

Genmab A/S Stock Performance

NASDAQ:GMAB opened at $25.27 on Friday. Genmab A/S Sponsored ADR has a twelve month low of $20.23 and a twelve month high of $35.43. The company has a current ratio of 2.18, a quick ratio of 2.17 and a debt-to-equity ratio of 0.87. The company has a 50-day moving average of $26.56 and a 200-day moving average of $29.03. The firm has a market cap of $15.76 billion, a price-to-earnings ratio of 19.14, a price-to-earnings-growth ratio of 1.51 and a beta of 0.85.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.